Patient & Visitor InformationContact Us
  • SECRET Study

  • Principal Investigator:  Kenneth Korr, MD
    Sponsored by:  Cardiovascular Clinical Science Foundation

    The SECRET Trial is a randomized, double-blind, placebo controlled study of short term clinical effects of Tolvaptan 30mg daily in patients hospitalized for worsening heart failure with challenging volume management.

    Eligibility:
    • Patients who are hospitalized for worsening heart failure and randomized within 36 hours of initial presentation.
    • History of treated heart failure for at least 30 days
    • Shortness of breath

    Participation includes:
    • Patients will receive study drug or a placebo for up to 7 days while in the hospital.  
    • There will be blood tests and will have liver function monitored while on study drug.  
    • A clinic visits at Day 7  
    • A phone call follow-up at Day 30
    • Participation in this study will be approximately one month. 
    Cardiovascular Clinical Science Foundation (CCSF) is studying an investigational drug called Tolvaptan.  An investigational drug is a drug that is being studied for approval by the United States Food and Drug Administration (FDA). This drug is not available in the United States for the treatment of congestive heart failure. Tolvaptan is being studied as a possible treatment for congestive heart failure (CHF). Increased fluid and not being able to remove fluid from the body are problems linked to CHF.  

    For more information, contact:
    Cardiovascular Research
    The Miriam Hospital
    Lori-Ann DeSimone, RN
    401-793-4105